Alliance / A151216
Trial Overview
Official Title
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Study Purpose
To study the genes of tumor cells to determine if these results will help physicians select the best treatment options for patients with genetic changes.
Diagnosis
Stage IB-IIIA Non-Small Cell Lung CancerEligibility
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
No prior chemotherapy or radiation therapy for this lung cancer
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
- Alliance A081105 (if EGFR positive)
- CTSU E4512 (if ALK positive)
- CTSU EA5142 (if PD-L1 positive)
For more information, click the link below:
https://clinicaltrials.gov/study/NCT02194738?term=A151216&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
A151216